Impact of helicobacter pylori infection on the activities of urease and lipase enzymes in patients with giardiasis

The study of the effect of Giardia lamblia and Helicobacter pylori organisms coexistence on the activities of urease and lipase enzymes was the aim of this work which was done through choosing 50 cases of giardiasis in addition to 10 normal individuals chosen as a control group [free from giardiasis]. It is well known that H. pylori is considered one of the most important causes of gastric and duodenal inflammations which could predispose to ulcers and hypochlorhydria leading to increased susceptibility to giardiasis as it is known that HCl acts as a chemical barrier to microbes. The biochemical tests were done to investigate the activity of both urease and lipase enzymes extracted from the gastric juice of patients and controls. A significant increase in urease activity in the group having combined infection [giardiasis and H.pylori] than the group infected with G.lamblia alone and the control group was found. The same findings were obtained regarding the lipase activity. In the present work, both infections H. pylori and G. lamblia coexisted in 75% of epigastric pain cases which could be explained on the basis that both organisms predispose to each other

Triclabendazole in the treatment of established human fascioliasis

The tolerance and efficacy of triclabendazole CGP 23030, specially prepared for human use, were assessed in 50 patients in the chronic phase of fascioliasis. After clinical examination, investigation and ultrasonography of the liver and biliary system, triclabendazole 10 mg/kg, either as a single or split dose, was administered. The clinical picture was studied daily for six days and the investigations were repeated 6, 30 and 60 days after treatment. The drug was tolerated. Its side-effects, which included upper abdominal pain, mild fever and limited derangement of liver function, were considered negligible. The cure rate at 2 months was 94% when assessed by the disappearance of eggs in stools and 88% when assessed by both the absence of eggs in stools and of worms in the biliary system. The use of triclabendazole for the treatment of human fascioliasis was found to be justified

Triclabendazole in treatment of human fascioliasis

Recent outbreaks of human fascioliasis had been reported in Alexandria and Behira provinces. The presentation of Fasciola species infection in man varies with the age of the patient and with the stage of the disease. Many drugs have been tried in human fascioliasis but still the drug of choice remains to be determined. Triclabendazole is a novel antihelminth that affects both immature and mature stages of Fasciola infection. Previous preliminary studies showed that the drug has a promising value in treatment of human fascioliasis. The present study was carried out on 54 patients with fascioliasis, 26 of them were incubating patients and 28 with established fascioliasis. Regarding the age, 37 were children and 17 were adult patients. Patients were assessed clinically and by laboratory investigations. They were treated with triclabendazole suspension 10% solution in a dose of 20 mg/kg body weight on fasting stomach. The study revealed that the drug is finely tolerated safe and effective. Acute or incubating fascioliasis in children is more preferably treated by two doses [second dose raised cure rate from 37 to 83%]. Adults require a single dose whatever the stage of the disease [cure rate of the single dose was 78-90%]

Prevalence of HCV antibody and HBs antigen in schistosomal patients in relation to some risk factors

In this study 60 schistosomal patients were screened for HCV antibodies and HBs Antigen and were analyzed for various medical risk factors in order to investigate the possible relation between schistosomiasis and HCV infection and the effect of their concomitant presence on liver functions. All schistosomal patients were HBs antigen negative. Anti-HCV was present in 43.3% of the schistosomal patients. The prevalence of anti-HCV was significantly higher in patients over the age of 20 years [60%] compared to 10% under 20 years of age.results indicated that 65.38% of HCV positive patients were treated with injections while 76.47% of HCV negative patients have not received parentral treatment. ALT was elevated in 23.07% of schistosomal HCV positive patients compared to none of the HCV negative patients, indicating mild hepatocellular injury. AST was elevated in 50% of both HCV positive and negative schistosomal patients with a mean value higher in HCV positive patients, indicating that association of HCV with schistosomiasis might have a greater impact on liver status

Helicobacter pylori and upper gastrointestinal mucosal changes in schistosomal hepatic fibrosis

Sixty patients with schistosomal hepatic fibrosis undergoing gastrointestinal endoscopy were included in this study. Patients were divided into two groups: Group [A]: 42 patients with previous history of gastrointestinal bleeding and group [B]: 18 patients with no history of bleeding. Abnormal mucosal findings other than oesophageal varices were found in 40.5 percent in group [A] and 33.3 percent in group [B]. CLO test for detection of Helicobacter pylori infection was performed for every case. The incidence of Helicobacter Pylori infection in both groups as regards cases with abnormal mucosal findings was 100 percent. In cases with no mucosal abnormality it was 32 percent and 16.4 percent respectively. In conclusion, these findings would suggest Helicobacter Pylori infection as a possible aetiological factor in mucosal changes and peptic ulcer disease in schistosomal hepatic fibrosis and would suggest giving CLO positive patients whether they have or have no mucosal changes the tripple therapy to eradicate Helicobacter Pylori infection